Janus Henderson Group PLC Puma Biotechnology, Inc. Transaction History

Janus Henderson Group PLC

$194 Billion
Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 745,541 shares of PBYI stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

745,541

Holding current value

$3.63 Million

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.74 - $3.72 $2.04 Million - $2.77 Million	745,541 New	745,541 $2.56 Million
Q2 2019 Jul 31, 2019	SELL	$12.3 - $35.76 $26.7 Million - $77.6 Million	-2,170,423 Closed	0 $0
Q1 2019 Apr 30, 2019	BUY	$20.77 - $42.37 $6.41 Million - $13.1 Million	308,479 Added 16.57%	2,170,423 $84.2 Million
Q4 2018 Feb 06, 2019	SELL	$20.07 - $46.7 $5.71 Million - $13.3 Million	-284,516 Reduced 13.26%	1,861,944 $37.9 Million
Q3 2018 Nov 09, 2018	SELL	$41.2 - $59.85 $47.6 Million - $69.2 Million	-1,155,561 Reduced 35.0%	2,146,460 $98.4 Million
Q2 2018 Aug 10, 2018	SELL	$48.3 - $68.25 $57 Million - $80.6 Million	-1,180,285 Reduced 26.33%	3,302,021 $195 Million
Q1 2018 May 14, 2018	BUY	$59.7 - $99.25 $7.56 Million - $12.6 Million	126,663 Added 2.91%	4,482,306 $305 Million
Q4 2017 Feb 09, 2018	BUY	$93.85 - $132.45 $231 Million - $326 Million	2,464,742 Added 130.35%	4,355,643 $431 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $2.4 Million - $3.98 Million	33,270 Added 1.79%	1,890,901 $0
Q2 2017 Aug 17, 2017	BUY	N/A	1,857,631	1,857,631 $162 Million

Others Institutions Holding PBYI

# of Institutions

124

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $222M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Puma Biotechnology, Inc. Transaction History